Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Long-Term Deferred Tax: 2010-2024

Historic Long-Term Deferred Tax for China Pharma Holdings (CPHI) over the last 9 years, with Dec 2024 value amounting to $21.7 million.

  • China Pharma Holdings' Long-Term Deferred Tax was N/A to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year change of. This contributed to the annual value of $21.7 million for FY2024, which is 0.78% up from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Long-Term Deferred Tax is $21.7 million, which was up 0.78% from $21.5 million recorded in FY2023.
  • China Pharma Holdings' 5-year Long-Term Deferred Tax high stood at $27.7 million for FY2020, and its period low was $21.5 million during FY2023.
  • For the 3-year period, China Pharma Holdings' Long-Term Deferred Tax averaged around $21.7 million, with its median value being $21.7 million (2024).
  • As far as peak fluctuations go, China Pharma Holdings' Long-Term Deferred Tax fell by 13.32% in 2021, and later climbed by 0.78% in 2024.
  • Yearly analysis of 5 years shows China Pharma Holdings' Long-Term Deferred Tax stood at $27.7 million in 2020, then declined by 13.32% to $24.0 million in 2021, then declined by 8.33% to $22.0 million in 2022, then declined by 2.07% to $21.5 million in 2023, then climbed by 0.78% to $21.7 million in 2024.